首页 | 官方网站   微博 | 高级检索  
     

微管相关蛋白2在胰腺神经内分泌肿瘤组织中的表达及预后意义
引用本文:宋甜甜,肖雨,白春梅,李乃适,陈洁,赵大春,宋玉立,金凯舟,朱丽明,于润,虞先濬,陈原稼.微管相关蛋白2在胰腺神经内分泌肿瘤组织中的表达及预后意义[J].中国肿瘤临床,2017,44(11):532-538.
作者姓名:宋甜甜  肖雨  白春梅  李乃适  陈洁  赵大春  宋玉立  金凯舟  朱丽明  于润  虞先濬  陈原稼
作者单位:①.中国医学科学院,北京协和医学院,北京协和医院消化内科(北京市100730)
基金项目:the National Natural Sciences Foundation of China (No. 81450015) 本文课题受国家自然科学基金应急管理项目(81450015)
摘    要:   目的   探索微管相关蛋白2(microtubule-associated protein 2,MAP2)与微管相关蛋白1B(microtubule-associated protein 1B,MAP1B)在预测胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,PNETs)患者预后中的意义。   方法   收集1999年12月至2016年12月来自于北京协和医院、中山大学附属第一医院、复旦大学上海癌症中心和Cedars-Sinai医学中心(洛杉矶)193例患者的193个原发肿瘤标本。免疫组织化学染色法分别检测193例、120例PNETs组织中MAP2、MAP1B的表达,随后分析蛋白表达与患者临床病理特征及预后的关系。   结果   MAP2和MAP1B在PNETs患者中的阳性率分别为45.6%(88/193)和64.2%(77/120)。MAP2表达阳性的患者的总生存好于阴性患者(P=0.012)。另外,MAP2阳性Ⅱ、Ⅲ期患者的总生存也优于阴性者(P=0.017)。然而,MAP1B的表达与肿瘤大小、转移、肿瘤组织学分级、临床分期、总生存、无病生存均无相关性(P > 0.05)。   结论   MAP2为潜在的预测PNETs患者预后的指标。 

关 键 词:微管相关蛋白2    胰腺神经内分泌肿瘤    预后
收稿时间:2017-02-01

Expression of microtubule-associated protein 2 correlates with better prognosis of pancreatic neuroendocrine tumors
Tiantian SONG,Yu XIAO,Chunmei BAI,Naishi LI,Jie CHEN,Dachun ZHAO,Yuli SONG,Kaizhou JIN,Liming ZHU,Run YU,Xianjun YU,Yuanjia CHEN.Expression of microtubule-associated protein 2 correlates with better prognosis of pancreatic neuroendocrine tumors[J].Chinese Journal of Clinical Oncology,2017,44(11):532-538.
Authors:Tiantian SONG  Yu XIAO  Chunmei BAI  Naishi LI  Jie CHEN  Dachun ZHAO  Yuli SONG  Kaizhou JIN  Liming ZHU  Run YU  Xianjun YU  Yuanjia CHEN
Abstract:Objective: To determine whether microtubule-associated protein 2 (MAP2) and microtubule-associated protein 1B (MAP1B) could be prognostic biomarkers for patients with pancreatic neuroendocrine tumors (PNETs). Methods:With immunohisto-chemical staining, the expressions of MAP2 and MAP1B were examined in 193 and 120 primary tumors and peritumoral tissues, re-spectively. Then, the relationship between the expression of each protein and clinicopathological characteristics, including prognosis was analyzed. Results:MAP2 and MAP1B were expressed in 88 of 193 (45.6%) and 77 of 120 (64.2%) tumors, respectively. The expres-sion of MAP2 was significantly associated with the favorable overall survival of patients with PNETs (P=0.012). Moreover, MAP2 expres-sion was associated with the improved overall survival in a subset of patients with stageⅡand stageⅢtumors (P=0.017). The MAP1B expression did not correlate with other clinicopathological features and prognosis. Conclusion:MAP2 could be a novel, independent prognostcbiomarker for PNETs.
Keywords:microtubule-associated protein 2  pancreatic neuroendocrine tumors  prognosis
本文献已被 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号